Zanoni P, Steindl K, Sticht H, Oneda B, Joset P, Ivanovski I, et al. The genetic landscape and clinical implication of pediatric Moyamoya angiopathy in an international cohort. Eur J Hum Genet. 2023. https://doi.org/10.1038/s41431-023-01320-0.
Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56:34–40.
Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PloS One. 2011;6:e22542.
Zhang Q, Liu Y, Zhang D, Wang R, Zhang Y, Wang S, et al. RNF213 as the major susceptibility gene for Chinese patients with moyamoya disease and its clinical relevance. J Neurosurg. 2017;126:1106–13.
Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, Youssefian S. A new horizon of moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med. 2016;21:55–70.
Ma J, Liu Y, Ma L, Huang S, Li H, You C. RNF213 polymorphism and Moyamoya disease: a systematic review and meta-analysis. Neurol India. 2013;61:35–9.
Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78:803–10.
Yamaguchi E, Yoshimoto T, Ogura S, Saito K, Saito S, Hattori Y, et al. Association of the RNF213 p.R4810K variant with the outer diameter of cervical arteries in patients with ischemic stroke. Stroke: Vasc Interventional Neurol 2022;2:e000298.
Kobayashi H, Kabata R, Kinoshita H, Morimoto T, Ono K, Takeda M, et al. Rare variants in RNF213, a susceptibility gene for moyamoya disease, are found in patients with pulmonary hypertension and aggravate hypoxia-induced pulmonary hypertension in mice. Pulm Circ. 2018;8:2045894018778155.
Bang OY, Chung J-W, Kim DH, Won H-H, Yeon JY, Ki C-S, et al. Moyamoya disease and spectrums of RNF213 vasculopathy. Transl Stroke Res. 2019. https://doi.org/10.1007/s12975-019-00743-6.
Kim JY, Cho H. Renovascular hypertension and RNF213 p.R4810K variant in Korean children with Moyamoya disease. Clin Nephrol. 2021;96:105–11.
Kobayashi H, Matsuda Y, Hitomi T, Okuda H, Shioi H, Matsuda T, et al. Biochemical and functional characterization of RNF213 (Mysterin) R4810K, a susceptibility mutation of moyamoya disease, in angiogenesis in vitro and in vivo. J Am Heart Assoc. 2015;4:e002146.
Ohkubo K, Sakai Y, Inoue H, Akamine S, Ishizaki Y, Matsushita Y, et al. Moyamoya disease susceptibility gene RNF213 links inflammatory and angiogenic signals in endothelial cells. Sci Rep. 2015;5:13191.
Phi JH, Choi JW, Seong MW, Kim T, Moon YJ, Lee J, et al. Association between moyamoya syndrome and the RNF213 c.14576G>A variant in patients with neurofibromatosis Type 1. J Neurosurg Pediatr. 2016;17:717–22.
Ikeuchi Y, Kitayama J, Sahara N, Okata T, Miyake N, Matsumoto N, et al. Filamin A variant as a possible second-hit gene promoting moyamoya disease-like vascular formation associated with RNF213 p.R4810K variant. Neurol Genet. 2022;8:e200017.
Chong PF, Ogata R, Kobayashi H, Koizumi A, Kira R. Early onset of moyamoya syndrome in a Down syndrome patient with the genetic variant RNF213 p.R4810K. Brain Dev. 2015;37:822–4.
Kim SY, Kim MJ, Kim SJ, Lee JE, Chae JH, Ko JM. A case of CHOPS syndrome accompanied with moyamoya disease and systemic vasculopathy. Brain Dev. 2021;43:454–8.
Kaseka ML, Slim M, Muthusami P, Dirks PB, Westmacott R, Kassner A, et al. Distinct clinical and radiographic phenotypes in pediatric patients with moyamoya. Pediatr Neurol. 2021;120:18–26.
Al-Jefri A, Siddiqui K, Al-Oraibi A, Al-Seraihy A, Al Ahmari A, Ghemlas I, et al. Hematopoietic stem cell transplantation stabilizes cerebral vasculopathy in high-risk pediatric sickle cell disease patients: evidence from a referral transplant center. J Hematol. 2022;11:8–14.
Asselman C, Hemelsoet D, Eggermont D, Dermaut B, Impens F. Moyamoya disease emerging as an immune-related angiopathy. Trends Mol Med. 2022;28:939–50.
Ge P, Zhang Q, Ye X, Liu X, Deng X, Wang J, et al. Modifiable risk factors associated with moyamoya disease: a case-control study. Stroke 2020;51:2472–9.
Cheong PL, Lee WT, Liu HM, Lin KH. Moyamoya syndrome with inherited proteins C and S deficiency: report of one case. Acta Paediatr Taiwan. 2005;46:31–4.
Tsuda H, Hattori S, Tanabe S, Nishioka S, Matsushima T, Ikezaki K, et al. Thrombophilia found in patients with moyamoya disease. Clin Neurol Neurosurg. 1997;99:S229–33.
Bonduel M, Hepner M, Sciuccati G, Torres AF, Tenembaum S. Prothrombotic disorders in children with moyamoya syndrome. Stroke. 2001;32:1786–92.
Yamada I, Himeno Y, Matsushima Y, Shibuya H. Renal artery lesions in patients with moyamoya disease: angiographic findings. Stroke. 2000;31:733–7.
Baek JW, Jo K-I, Park JJ, Jeon P, Kim KH. Prevalence and clinical implications of renal artery stenosis in pediatric moyamoya disease. Eur J Paediatr Neurol. 2016;20:20–4.
Morimoto T, Mineharu Y, Ono K, Nakatochi M, Ichihara S, Kabata R, et al. Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease. PLoS One. 2017;12:e0175649.
Jee TK, Yeon JY, Kim SM, Bang OY, Kim JS, Hong SC. Prospective screening of extracranial systemic arteriopathy in young adults with moyamoya disease. J Am Heart Assoc. 2020;9:e016670.
Gaillard J, Klein J, Duran D, Storey A, Scott RM, Kahle K, et al. Incidence, clinical features, and treatment of familial moyamoya in pediatric patients: a single-institution series. J Neurosurg Pediatr. 2017;19:553–9.